Environmental Mutagenesis & Genomics Society
50th Annual Meeting, Washington DC
September 19-23, 2019 - Capital Hilton Washington DC
Environmental Mutagenesis and Genomics: The Next Fifty Years
Special Symposium
Registration
Important Dates
Registration
3/4/19-Registration is now Open
7/27/19-Early Bird Registration Ends
8/19/19-Advanced Registration Ends
Abstracts
2/22/19-Abstract Submission is now Open
5/15/19-Abstract Submission Deadline
8/29/19-Late Abstracts Deadline
Travel Awards
Travel Award Form Available
5/15/19-Travel Award Deadline
Hotel Information
2/27/19-Reservations Open
8/21/19-Reservation Deadline
EMGS Welcomes You
The EMGS welcomes members and attendees from across the US and around the world. Our diversity is essential to our success, and as your national professional society, we are committed to providing a safe and supportive forum for the communication of world-class science. The EMGS Diversity and Inclusion committee sends a special welcome to members of the LGBT community. Please reach out to any member of the EMGS Diversity and Inclusion Committee with your comments.
EMGS Workshops
September 19th, 2019
3:00 PM - 5:00 PM
Council Meeting
Room: Massachusetts
8:00 AM - 12:00 PM
Scientific and Regulatory Updates on Non-Mutagenic and Mutagenic Impurities in Pharmaceuticals
Chair: Patricia Escobar, Merck Inc. and Brinda Mahadevan, Abbot
Room: Pan American
8:00-8:10 AM
Introduction
Brinda Mahadevan, Abbott Healthcare Pvt. Ltd, Mumbai, India
8:10-8:40 AM
Update of IQ Consortium – Non Mutagenic Impurities (NMI)
Joel Bercu, Gilead USA
8:40-9:10 AMConsiderations for Deriving Non-Mutagenic (NMI) Exposure Limits
Mark Powley, Merck & Co., Inc., USA
9:10-9:40 AMRegulatory perspective on Non-mutagenic impurities (NMI)
Tim McGovern, FDA
9:40-10:00 AM
Break
Update on the DrugSafe IQ consortium on mutagenic Impurities (QSAR review of impurities)
John Nicolette, AbbVie USA
10:30-11:00 AM
ICH M7 and Biotherapeutics: Out of Scope but Relevant
Zhanna Sobol, Pfizer USA
Regulatory Perspective on Mutagenic Impurities and ICH M7
Roland Frotschl, EMA, bfarm, Germany
11:30-11:50 AMQ&A followed by a panel discussion
8:45 AM - 3:30 PM
Heritable Hazards of Smoking: Applying the “Clean Sheet” Framework to Further Science and Policy
Co-Chairs: Francesco Marchetti, Health Canada, Jill Escher, Escher Fund for Autism, Young Investigator Co-chair: Abigail Bline, UCLA
Organizing Committee: Abigail Bline, UCLA, Kerry Dearfield, Retired (formerly at USDA and EPA), David DeMarini, US EPA, Jill Escher, Francesco Marchetti, Carole Yauk, Health Canada
Room: Statler
8:45-9:00 AM
Welcome, Opening Remarks, and Introductions
Jill Escher, Escher Fund for Autism
9:00-9:20 AM
The Clean Sheet Initiative and Its Potential to Identify the Risks of Heritable Consequences of Tobacco Smoke Exposures
Kerry L. Dearfield, Retired (formerly at USDA and EPA), Burke, VA
9:20-9:40 AM
Rationale for This Workshop: Growing Concern Regarding Heritable and Intergenerational Effects from Environmental Exposures
Carole L. Yauk, Health Canada
9:40-10:00 AM
The Potentially Vulnerable Periods of Exposure to the Male and Female Germline
Jacquetta Trasler, McGill University, Montreal, ON, Canada
10:00-10:20 AM
Break
10:20-10:40 AM
Tobacco Smoke Exposure: Hazardous Components of Tobacco and Related products; Broad Overview of Known Health Effects; Tobacco-Induced Male Germ Cell and Heritable Effects
Francesco Marchetti, Health Canada
10:40-11:00 AM
Male-Mediated Heritable Epigenetic Effects
Jacquetta Trasler, McGill University, Montreal, ON, Canada
11:00-11:20 AM
Overview of Asthma and Allergy Epidemiology: Epigenetic Studies of Transgenerational Effects of Smoking
John Holloway, University of Southhampton, UK
11:20-11:40 AM
Multigenerational Transmission of Hyperactivity/ADHD
Pradeep Bhide, Florida State University, Tallahassee, FL, USA
11:40-11:50
Grandmaternal Smoking and Risk for ADHD
Gyeyoon Yim, ScD candidate, Harvard T.H. Chan School of Public Health, MA, USA
11:50-12:10 PM
The RHINESSA Cohort, a Three-Generation Study on the Association of Tobacco Smoking with Asthma
Cecillie Svanes, University of Bergen, Norway
12:10-12:30 PM
Panel Discussion of the Evidence
12:30-1:30 PM
Lunch (provided)
1:30-2:00 PM
Toxicology of E-cigarettes
Ilona Jaspers, University of North Carolina, NC, USA
2:00-2:30 PM
Discussants
Implications for Bioethics
Anne Le Goff, Institute for Society and Genetics, UCLA, CA, USA
Implications for Public Health Advocacy
Laurent Huber, Executive Director, ASH, Washington, DC, USA
2:30-3:30 PM
Directed Discussion and Consensus Opinion
Methods and data to study intergenerational effects of these products and how to apply the Clean Sheet Framework. Is there a need for regulatory policy to emphasize germ cell risk in addition to somatic cell risk? Next steps?
12:00 - 4:30 PM
OECD Assessment of Miniaturized Ames Assays: Results and Recommendations
Co-chairs: Birgit Mertens, Sciensano, Brussels, Belgium, Leon F. Stankowski, Jr. Charles River Laboratories, Skokie, IL, USA
Room: New York
12:00-12:15 PM
Pick up Box Lunch (provided)
12:15-12:30 PM
Overview of OECD Process to Evaluate Miniaturized Ames Assays
Birgit Mertens, Sciensano, Brussels, Belgium
12:30-1:00 PM
The 6-Well Ames Assay
John Nicolette, AbbVie, North Chicago, IL, USA
1:00-1:30 PM
The 24-Well Ames Assay
Leon F. Stankowski, Jr., Charles River Laboratories, Skokie, IL, USA
1:30-2:00 PM
The Ames II/MPF Assay
Kamala Pant, BioReliance, Rockville, MD, USA
2:00-2:30 PM
Technical Comparisons Among Assays
Birgit Mertens, Sciensano, Brussels, Belgium
2:30-3:00 PM
Coffee Break
3:00-3:45 PM
Qualitative and Quantitative Comparisons of Assays
Paul White, Health Canada
3:45-4:30 PM
Discussion and Closing Summary
Birgit Mertens, Sciensano, Brussels, Belgium
5:30 PM - 6:45 PM
EMGS President's Reception
Room: Congressional
7:00 PM - 8:00 PM
EMGS Presidential Keynote Address
The Fidelity of Eukaryotic Nuclear DNA Replication
Thomas A. Kunkel, NIH Distinguished Investigator
Room: Presidential Ballroom